Ionis's weak Tryngolza launch clouds Arrowhead's severe-hypertriglyceridemia bet
- Ionis reported flat Tryngolza sales of $9M and cut 2026 sales guidance to $50M, citing a slower ramp; Stifel said it was worse than already low expectations.
- Arrowhead's Redemplo earned $6.6M in its first full fiscal year after its November 2025 approval in FCS; Arrowhead has filed it in severe hypertriglyceridemia (sHTG) and joined FDA's STAR pilot.
- CEO Chris Anzalone blamed Ionis's communication and execution rather than the market; Jefferies sees up to $2.5B in sales but calls the near term tricky.
💡 Points Based on public reports
Both drugs are tuned to the same triglyceride-lowering story, so Ionis's slow FCS launch is a fair read-across for Arrowhead's rare-disease start, but the real bet is sHTG, where the patient pool is orders of magnitude larger and the buyer is a cardiologist, not a rare-disease center. Arrowhead's answer is execution; what it needs to show is a pancreatitis-prevention story that payers will pay for, not just lower lipids.
📰 Source · BioSpace ↗ Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings